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ABSTRACT
A Rational Design Approach to Developing Second Generation Fabry Disease
Treatments
September 2020
MATTHEW C. METCALF, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Scott Garman

Fabry disease is an X-linked lysosomal storage disorder that affects
approximately 1 in 40,000 males in its classical form and as many as 1:4,600 in its
late-onset form [1]. The disease is caused by mutations in the gene encoding αgalactosidase (α-GAL), which results in deficient levels of α-GAL activity in the
lysosomes of patients [2, 3]. This lack of enzymatic activity causes macromolecular
substrates to accumulate in tissues, and can result in a wide range of symptoms such
as impaired renal and cardiac function [4]. The severity of disease is linked to the
amount of residual enzyme activity [5, 6]. Mutations resulting in little to no residual
activity lead to the more severe classical form of the disease, whereas those that
retain a fraction of wild-type enzyme levels lead to the less severe late-onset form of
the disease. The FDA has approved both enzyme replacement therapy (ERT) and
pharmacological chaperone therapy (PCT) for the treatment of Fabry disease.
ERT involves the intravenous injection of recombinant α-GAL. The injected
enzyme is delivered to the lysosome through the binding of extracellular mannose6-phosphate receptors. ERT has been shown to clear accumulated substrate in the
majority of tissue types, and has shown to slow the impairment of organ function
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typically associated with the disease [7, 8]. Despite being broadly efficacious for the
treatment of both forms of Fabry disease, additional treatment options were
developed.
PCT recently received approval for the treatment of a select number of Fabry
patients. The treatment involves the oral administration of Galafold™, a small
molecule also known as 1-deoxygalactonojirimycin (DGJ). DGJ is a potent competitive
inhibitor of α-GAL, and acts by stabilizing mutant forms of α-GAL as they traffic to
the lysosome [9, 10]. Only a portion of Fabry patients are approved to receive this
treatment [11]. These patients possess one of the 348 genetic mutations for which this
treatment has been found applicable. The majority of these patients have the late-onset
form of the disease and possess some level of residual α-GAL activity. Despite
the success of PCT and ERT at treating a broad number of patients there still exists a
number of shortcomings associated with either treatment.
One such shortcoming is the immunogenicity associated with the
recombinant ERT enzymes. 88% of patients receiving ERT develop immune
responses including both IgG and IgE based reactions [12-14]. It is our belief that the
immune response is present because classical Fabry patients produce no correctly
folded α-GAL, and when correctly folded α-GAL is presented to the immune system
it is treated as foreign. This results in immune response and is likely to trigger the
formation of neutralizing antibodies. In order to bypass this issue, we interconverted
the active sites of α-GAL and a highly homologous human enzyme, α-NAGAL. The
engineered enzymes possess lower catalytic efficiency than the wild-type
counterparts, but have acquired the selectivity of their counterparts. We confirmed
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this through enzymatic characterization and through x-ray crystallography. Most
importantly we showed that enzymes retain their native antigenicity. By
engineering novel functionality into previously existing protein scaffolds we have
highlighted a rational approach to engineering less immunogenic therapeutics.
In addition to possessing undesirable immunogenic properties, the efficiency
of ERT in the clearance of substrate in podocyte cells has come into question [15, 16].
These cells play a critical role in the function of the glomerular filtration barrier and
ultimately kidney function. Due to the function of these cells, they form the third
layer of filtration as well as performing vital role in the structure of glomerular
capillaries, they are naturally a problematic cell type for serum-circulated ERT
molecules to reach. Permeability of this barrier has been shown to be dependent on
charge and molecular diameter, with permeability having an inverse relationship
with molecular diameter. By engineering mutations that disrupt the dimer interface
of α-GAL we have successfully expressed and purified a monomeric form of the
enzyme, which possesses slightly lower than wild-type levels of activity and
stability. The monomeric α-GAL may provide an excellent point of entry towards
engineering a more potent ERT molecule for the treatment of renal variants of Fabry
disease.
While investigating the selectivity and affinity of α-Gal and α-NAGAL towards
galactose and α-N-acetylgalactosamine analogs, we observed that at concentrations
similar to those used in clinical trials DGJ significantly inhibits human β-GAL. This
observation led us to further investigate the effect of α-linked functional groups
attached to the position corresponding to C1 in a galactose scaffold. In DGJ and the
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2-acetamido variant, DGJNAc, this position is occupied by a hydrogen. We utilized
inhibition assays and x-ray crystallography to probe the effect of certain functional
groups at this position on specificity and affinity towards α-GAL or α-NAGAL. We
determined that these groups provided little to no change in affinity, but
provided increased specificity towards α-selecting active sites. These findings coupled
with previous studies performed by members of the Garman lab provide a clear set
of guidelines towards developing ligands specific towards either α-GAL α-NAGAL.

viii

TABLE OF CONTENTS
Page

ABSTRACT……………………………………………………………………………...v
LIST OF TABLES .........................................................................................................xiii
LIST OF FIGURES ........................................................................................................xvi
1.

BACKGROUND ....................................................................................................1
Lysosomes................................................................................................................1
Lysosomal trafficking ..............................................................................................1
Lysosomal storage disorders ....................................................................................2
Fabry disease ............................................................................................................4
Human -galactosidase............................................................................................6
Treatments................................................................................................................7
Enzyme replacement therapy ...................................................................................8
Pharmacological chaperone therapy ......................................................................11

2.

INTERCONVERSION OF THE SPECIFICITIES OF HUMAN
LYSOSOMAL ENZYMES ASSOCIATED WITH FABRY AND
SCHINDLER DISEASE ......................................................................................15
Abstract ..................................................................................................................15
Introduction ............................................................................................................15
Results ....................................................................................................................18
Biochemical Characterization of -GALSA and -NAGALEL ...............18
Enzymatic activity -GALSA and -NAGALEL .....................................19
Crystal structure of -GALSA ..................................................................21
ix

Discussion ..............................................................................................................22
Enzyme replacement therapy .....................................................................22
Properties of the engineered enzymes........................................................23
Experimental Procedures .......................................................................................26
Molecular biology ......................................................................................26
Cell transfection .........................................................................................26
Protein expression and purification ...........................................................27
Kinetic assays.............................................................................................27
Crystallizaton and x-ray data collection ....................................................28
3.

THE RATIONAL DESIGN OF A POTENTIAL SECOND GENERATION
ERT THERAPEUTIC WITH INCREASED RENAL EFFICACY ...............34
Introduction ............................................................................................................34
Results ....................................................................................................................36
-GALF273G+W277G retains significant enzymatic activity ......................36
-GALF273G+W277G shows increased membrane permeability ...............37
-GALF273G+W277G displays altered mobility on size-exclusion
columns ................................................................................................38
Discussion ..............................................................................................................40
Experimental Procedures .......................................................................................42
Molecular biology ......................................................................................42
Cell transfection .........................................................................................42
Protein expression and purification ...........................................................42
Size exclusion chromatography .................................................................43
Membrane permeability assay ...................................................................43

x

Enzyme kinetics .........................................................................................44
4.

Α-HOMO VARIANTS OF DEOXYGALACTONOJIRIMYCIN AND 2ACETAMIDO-1,2-DEOXY-D-GALACTONOJIRIMYCIN SHOW
INCREASED SPECIFICITY TOWARDS ENZYMES ASSOCIATED
WITH FABRY AND SCHINDLER DISEASE .................................................50
Introduction ............................................................................................................50
Results ....................................................................................................................54
Inhibitory properties of GJ, -HGJ, and -HGJNAc ................................54
Specificity of -HGJ ..................................................................................55
Atomic basis for iminosugar binding .........................................................55
Discussion ..............................................................................................................57
Experimental Procedures .......................................................................................59
Crystallization and x-ray data collection ...................................................59
Protein expression and purification ...........................................................60
Enzyme inhibition assays ...........................................................................61

5.

CONCLUSIONS AND FUTURE DIRECTIONS .............................................70

SUMMARY ......................................................................................................................75
APPENDIX .......................................................................................................................77
PHARMACOLOGICAL CHAPERONES FOR HUMAN Α-NACETYLGALACTOSAMINIDASE ...........................................................77
HUMAN ACID SPHINGOMYELINASE STRUCTURE PROVIDE
INSIGHT TO MOLECULAR BASIS OF NIEMANN-PICK
DISEASE ........................................................................................................84
LIGAND-PROMOTED PROTEIN FOLDING BY BIASED
KINETIC PARTITIONING .........................................................................95

xi

BIBLIOGRAPHY ..........................................................................................................107

xii

LIST OF TABLES

Table

Page

1.

Enzymatic parameters for enzyme interconversion study……………………….31

2.

Structural statistics for interconverted α-galactosidase………………………….33

3.

Summary of iminosugar inhibition constants against α-galactosidase and α-Nacetylgalactosaminidase…………………………………………………………65

4.

Structural statistics for iminosugar bound α-galactosidase……………………...69

xiii

LIST OF FIGURES
Figure

Page

1.

Cartoon representation of α-galactosidase structure ..............................................13

2.

Model of α-galactosidase secretion pathway .........................................................14

3.

Interconverted α-GAL and α-NAGAL structural and biochemical analysis…….30

4.

α-GALSA crystal structures………………………………………………………32

5.

Model of the α-GAL dimer interface…………………………………………….45

6.

Cross-species α-GAL amino acid sequence alignment…………………………..46

7.

Michaelis-Menten kinetics of α-GALSA…………………………………………47

8.

Membrane permeability assay of α-GALSA……………………………………..48

9.

Chromatogram of α-GALSA SEC elution………………………………………..49

10.

Structure of α-galactose and α-N-acetylgalactosamine and imino analogs……...62

11.

Enzymatic inhibition of α-GAL by GJ…………………………………………..63

12.

Enzymatic inhibition of α-GALand α-NAGAL by α-HGJ and α-HGJNAc……..64

13.

Crystal structure of α-GAL bound to GJ………………………………………...66

14.

Crystal structure of α-GAL bound to α-HGJ…………………………………….67

15.

Comparison of iminosugar binding to α-GAL……..…….………………………68

xiv

CHAPTER 1: Background
Lysosomes
Lysosomes are dynamic organelles responsible for several key functions of
eukaryotic cells. In addition to playing a crucial role in plasma membrane repair, nutrient
sensing, and cell signaling the organelle is the primary engine of macromolecular
degradation. Degradation is the function most commonly associated with the organelle,
as it is both the most thoroughly researched and provides the namesake of the organelle
(lysosome translates to digestive body in Greek). In order to degrade the vast amount of
substrates from both intracellular and extracellular sources the lysosome is equipped with
approximately 60 different soluble hydrolases including glycosidases, lipases, sulfatases,
peptidases, nucleases, and phosphatases [17]. When applied to a substrate this array of
hydrolases act in sequence to catabolize the macromolecule into basic
macromolecular/molecular subunits, which can then be utilized or secreted by the cell.
The lysosomal hydrolases do not act alone in their function to degrade
intracellular and extracellular substrate. The lysosome also contains numerous integral
lysosomal membrane proteins (LMPs), which act in a supportive role towards the
hydrolases. The approximate 25 LMPs present in the lysosome of mammals are
responsible for the acidification of the lysosomal lumen, substrate import, and the
trafficking of several lysosomal hydrolases into the lysosome.

Lysosomal trafficking
Proper lysosomal function can only be achieved if the required lysosomal
hydrolases and LMPs are successfully trafficked to the lysosome. Both classes of
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lysosomal protein utilize the secretory pathway and are translocated into the endoplasmic
reticulum using the Sec61 translocation channel. The proteins are then trafficked through
the trans-Golgi network towards lysosomes. The exact mechanism of this trafficking
varies between proteins and certain proteins have been shown to utilize multiple receptor
pathways. The most commonly utilized receptor pathway for the soluble hydrolases is the
mannose 6-phosphate pathway. In this pathway, N-linked glycans of the cargo molecule
are phosphorylated as the protein traverses the trans-Golgi network, and the
phosphorylated glycans are recognized by either the cation-dependent mannose 6phosphate receptor or the cation-independent receptor. The receptor/cargo complex then
associates with AP1 and/or GGA proteins to form clathrin-coated vesicles that traffic
through early and late endosomes towards mature lysosomes [18, 19]. Other known
pathway receptors utilized by the soluble hydrolases include the VPS10 domaincontaining receptors sortilin, SorLA, and SOR1-3, and the LMP LIMP-2 [20, 21]. Except
for LIMP-2, little is known of the trafficking pathways used by LMPs.

Lysosomal storage disorders
When a gene encoding a lysosomal enzyme is mutated in a fashion that the
resulting enzyme is functionally defective, the substrate of defective enzyme accumulates
in the lysosome. Accumulated substrates in critical cell types result in disease pathology.
The deficiencies as a group are referred to as lysosomal storage diseases, and together
they have an estimated incidence of ~1:7,000 live births [22]. The most common
lysosomal storage disorder is Gaucher disease. Other examples include Pompe disease,
Niemann-Pick diseases, Tay-Sachs disease, and Fabry disease.
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There are several scenarios that result in deficient levels of lysosomal enzyme
activity. In one scenario the patient possesses the gene for a wild-type lysosomal enzyme,
but possess defective genes encoding proteins involved in the trafficking machinery
required to deliver the enzyme to the lysosome. An example of this scenario, in which
deficient lysosomal enzyme activity results not from deficiencies in the enzyme, but
instead defects in a trafficking pathway, is inclusion-cell disease (I-cell disease, also
known as mucolipidosis II). I-cell disease results from a loss of N-acetylglucosamine-1phosphotransferase, the enzyme responsible for the transfer of GlcNAc-phosphate to Nlinked glycans of proteins trafficking through the secretory pathway [23-25]. Deficiencies
of the transferase prevent the formation of the mannose 6-phosphate moiety, normally
required for utilization of the mannose 6-phosphate receptor pathway, and results in
numerous lysosomal enzymes being secreted from the cell instead of being properly
targeted to the lysosome. In patients suffering from I-cell disease substrates from many
enzymes accumulate, and this disease has a severe phenotype as there many enzymes that
utilize mannose 6-phosphate receptor-dependent pathways [24]. An example of a defect
in a mannose 6-phosphate receptor-independent pathway leading to disease symptoms
can be observed in individuals with mutant forms of LIMP-2. Mutations in LIMP-2 lead
to action myoclonus-renal failure [26]. LIMP-2 has been shown to be critical for the
lysosomal targeting of β-glucocerebrosidase, the enzyme associated with Gaucher’s
disease [21, 27]. A subset of β-glucocerebrosidase mutants are localized to the ER, and
these mutants also lead to action myoclonus-renal failure [28]. The sub-cellular location
of the β-glucocerebrosidase mutants, shared phenotype, and the fact that the mutations
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are not located at the enzyme active-site imply that these Gaucher’s disease mutants are
the result of a loss of complex formation between β-glucocerebrosidase and LIMP-2.
Another scenario that leads to a deficiency in lysosomal enzyme is the presence of
mutations that directly alter the catalytic ability of the enzyme. This type of mutation
results in an enzyme that folds correctly, and is correctly trafficked to the lysosome, but
is unable to catalyze the hydrolysis of its substrate. These mutations are present in the
pools of reported disease-causing mutations for the majority of lysosomal storage
diseases, but only represent a small portion of these pools. This is illustrated by the fact
that most lysosomal enzymes have active sites comprising of only a dozen or so active
site residues, but often have hundreds of disease-causing mutations associated with the
associated disease.
The most common scenario resulting in a lysosomal storage disease is one in
which the disease mutations result in a destabilized protein. These variants of the
enzymes possess mutations that negatively impact the stability of the enzyme. In the case
of Fabry disease over 60% of mutations occur in the hydrophobic core of the enzyme,
and result in the enzyme being unable to evade the endoplasmic reticulum associated
degradation pathway (ERAD). A consequence of being recognized by ERAD folding
sensors is that the mutant enzyme is targeted for degradation.

Fabry disease
Fabry disease is the second most common lysosomal storage disorder. It is an Xlinked dominant disorder that affects ~1:40,000 men; however, studies screening
newborn children indicate that the disease may be underdiagnosed and may have an
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incidence rate as high as 1:4,600 [1]. This incidence rate is higher than that of the
commonly referenced incidence of lysosomal storage disorders as a whole, 1:7000. This
discrepancy hints that lysosomal storage diseases are heavily misdiagnosed as a group.
Fabry disease is caused by mutations in GLA, which encodes -galactosidase (-GAL)
[2, 3]. A consequence of this deficiency is the accumulation of substrate, primarily
globotriaosylceramide (Gb3) and lyso-globotriaosylceramide (lyos-Gb3), which
manifests disease symptoms[29, 30]. The severity of the disease is directly related to
amount of residual lysosomal -GAL enzyme levels, and the disease has been partitioned
into two forms depending on the amount residual lysosomal enzyme levels in males.
Classical Fabry disease is the most severe form of the disease. Patients suffering
from the classical form of the disease possess little to no residual -GAL activity, 5-15%
of normal levels [31]. Classical Fabry disease is characterized by chronic neuropathic
pain, skin lesions, lenticular and corneal opacities, angiokeratoma, hypohidrosis,
abdominal pain or bloating, as well as cardiac, renal, and cerebrovascular complications
[4]. The average lifespan of a person with Fabry disease is 58 years, and many of these
individuals require a kidney transplant during their life [32].
Late-onset Fabry disease is the less severe form of Fabry disease. Patients with
this form of the disease retain low levels of lysosomal -GAL enzyme activity, 5-35% of
normal levels [6]. Late-onset Fabry disease can further be divided into renal variants and
cardiac variants. Both variants do not display the symptoms associated with the classical
form such as skin lesions, angiokeratomas, lenticular and corneal opacities, and
neuropathic pain. Cardiac variants typically present cardiac symptoms between the fifth
and eighth decades of life. Symptoms associated with the cardiac variant include left
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ventricular hypertrophy, arrhythmias, and cardiomyopathy [30, 33, 34]. The renal variant
typically presents with proteinuria and later onset end-stage renal disease [1, 35, 36].
Female Fabry patients typically display less severe disease manifestations
compared to males due to GLA being located on the X chromosome [37]. The severity of
symptoms in heterozygous females is more difficult to predict based on GLA sequencing
due to lyonization also known as X-chromosome silencing, which randomly silences
gene expression on one X chromosome. In addition, the phenomenon of X-inactivation
skewing creates further X chromosome gene expression variation which differs from cell
to cell and can result in varying levels of residual enzyme activity between organs within
an individual [38, 39].

Human -galactosidase
Human -GAL exists exclusively as a homodimer, with each monomer consisting
of a -sandwich domain and a catalytic TIM barrel (Fig 1) [40]. -GAL is responsible for
catalyzing a double-displacement reaction resulting in the hydrolysis of terminal -linked
galactose from galactosides. It accomplishes this function using 13 residues in the active
site where aspartic acid 170 acts as the catalytic nucleophile, and aspartic acid 231 acts as
both an acid and a base throughout the reaction [41]. The remaining active site residues
are responsible for substrate specificity. The bulk of mutations that cause Fabry disease
result in single amino acid substitutions, 60% of which occur in the hydrophobic core of
the enzyme. Due to this observation, Fabry disease can be considered a protein foldingdisease.
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Treatments
There are a number of proposed treatments for Fabry disease and other lysosomal
storage diseases: pharmacological chaperone therapy (PCT), gene therapy, substrate
reduction therapy, hematopoietic cell transplantation, and enzyme replacement therapy
(ERT) [13, 42-44]. Presently the only approved treatments for Fabry disease are ERT and
PCT, with gene therapy and substrate reduction therapy in clinical trials.
Hematopoietic cell transplantation has been evaluated for a number of lysosomal
storage disorders. This treatment involves the introduction of enzyme-expressing cells
into the bone marrow, blood, and the central nervous system. This strategy has the
advantage of being able to deliver functional enzyme across the blood-brain barrier, and
is an appealing option for the treatment of lysosomal storages disorders with associated
neurological complications. Additionally, the infrastructure required to produce material
for this treatment is less demanding than those required for more traditional treatments,
and as such appears as an attractive option for diseases with very small patient
populations. The most extensive testing has been performed on α-mannosidosis patients,
and patients receiving this treatment in general showed less developmental retardation
than those receiving no treatment, although there was significant variation within the
patient pool [45]. Despite the promising results from these initial studies it should be
noted that there is considerable risk of serious complications associated with this
treatment as the procedure is invasive.
Substrate reduction therapy makes use of small molecules to limit production of
substrates associated with lysosomal storage disorders. This strategy has been applied to
the treatment of type 1 Gaucher disease in the form of Miglustat. Miglustat, also known
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as Zavesca®, acts by inhibiting glucosylceramide synthase, which catalyzes the first step
in glycosphingolipid synthesis [46]. Inhibition at this step in the synthesis pathway
prevents the production of any derivative glycosphingolipids, including the accumulated
substrate associated with Gaucher’s disease, glucocerebroside. In addition to lower levels
of glucocerebroside, all other glycosphingolipids are affected by this compound, and as a
result, miglustat has been suggested for the treatment of other lysosomal storage diseases
that accumulate glycosphingolipids, and has been approved for the treatment of
Niemann-Pick disease type C. It should be noted that initial proof-of-concept studies of
miglustat were carried out in a Fabry mouse model, due to limitations of Gaucher’s
disease mouse models of the time [47, 48]. Since the approval of miglustat, several
second generation substrate reduction therapy compounds possessing superior
pharmacokinetics and specificity and have been synthesized. Included in this second
generation are two compounds that have entered clinical trials for Fabry disease. One of
these compounds, venglustat, received FDA fast-track designation in 2015, and is
currently in phase 2 clinical trials. One obvious issue associated with the current crop of
substrate reduction therapies for lysosomal storage disorders is a lack of specificity, and
this is reflected in the fact that miglustat is only approved for Gaucher’s patients unable
to receive enzyme replacement therapy.

Enzyme replacement therapy
ERT was the initial treatment for Fabry disease (approved in the US in 2003 and
Europe in 2001). This treatment involves the intravenous injection of recombinantly
expressed -GAL. The enzyme binds either the mannose 6-phosphate receptor, sortilin,
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or megalin, at which point the cell undergoes endocytosis and the enzyme traffics to the
lysosome. This strategy can clear Gb3 and lyso-Gb3 deposits in the majority of tissues[8,
13, 49]. The two therapeutic products that have been developed for ERT of Fabry disease
are agalsidase alfa (Replagal) and agalsidase beta (Fabrayzyme). Fabrazyme® and
Replagal® are nearly identical except for the N-linked carbohydrates, resulting from the
different expression systems used to express the two recombinant enzymes (Fabrazyme®
is expressed in CHO cell lines and Replagal® is expressed in human cell lines). Detailed
analysis of the oligosaccharide structures of the Replagal® and Fabrazyme® ERT
proteins revealed that Fabrazyme® possessed higher degrees of sialyation and
phosphorylation [7]. Fabrazyme® was also shown to have a greater amount of enzyme
cellular uptake when applied to Fabry mice and cultured human Fabry fibroblasts, due to
the higher amount of mannose 6-phosphate glycans [50]. Additionally, it has been shown
that high sialic acid content results in higher serum half-life of glycoproteins [51]. This
discrepancy highlights the role glycosylation plays in ERT, and has spawned numerous
studies aimed towards glycol-engineered ERT molecules with greater efficacy.
Numerous approaches have been developed to produce recombinant enzymes
with higher mannose 6-phosphate content. Genzyme/Sanofi has pioneered methods to
produce mammalian expressed recombinant acid α-glucosidase and β-glucocerebrosidase
with exposed terminal mannose residues, through the use of in vitro exoglycosidase
treatments or kifunensine treatment during protein expression. Subsequent enzymatic
glycan modifications or chemical conjugations were then used to add mannose 6phosphate glycans [52-55]. In addition to chemical and enzymatic modifications of
mammalian expressed enzymes, alternate cell lines have been used to facilitate the
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production of recombinant enzymes with higher mannose 6-phosphate content. These
cultured carrot root cells produce recombinant proteins with plant pauci-mannose type
glycans, which do not require additional processes to expose terminal mannose residues
[56]. Unfortunately, the pauci-mannose glycans contain fucose and xylose residues
normally not found in mammals, and the use of these enzymes as ERT poses significant
concerns regarding immunogenicity.
A common issue associated with enzyme replacement therapy is immune
responses caused by the administration of the ERT drug. In the case of Fabrazyme® 5055% of patients receiving the therapy experience infusion reactions, and 88% of patients
develop IgG or IgE immune responses [8, 13, 14]. There is currently a pegylated form of
-GAL, Pegunigalsidase alfa, which is undergoing clinical trials as a Fabry treatment
[57]. This modified enzyme was designed with the goal of increasing plasma half-life,
and decreasing immunogenicity. Results from a 1 year phase 1/2 clinical trial show the
treatment maintained kidney function as measured by glomerular filtration rate and
showed the clearance of Gb3 inclusion bodies from most tissue [57]. Though the number
of patients in this study was limited, immune reactions to this treatment appear to be
mild, with only a small portion of patients developing IgG responses, which decreased
over the course of the trial. This approach represents one strategy to address serum
stability and immunogenicity, but it is likely that alternate strategies will also be needed
to address additional shortcomings identified in the current ERT drugs.
One of these additional shortcomings of ERT for Fabry disease that has come to
light in recent years is a deficiency in the ability of the drug to preserve podocyte health.
Unlike the near complete clearance of Gb3 inclusions in endothelial and mesangial cells
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after brief periods of ERT, podocyte Gb3 inclusions linger, although at levels lower than
those present prior to treatment [15]. In fact, podocyte foot effacement, a sign of
podocyte damage, has been shown to progress over time in patients receiving ERT [16].
Considering the crucial role of podocytes in kidney function, this observation highlights a
critical shortcoming of the current ERT drugs, one that should be prioritized during the
design of the next generation of Fabry ERT drugs.

Pharmacological chaperone therapy
The second approved treatment for Fabry disease is pharmacological chaperone
therapy (PCT). The principle guiding this strategy is that the addition of a ligand into the
folding environment; (the endoplasmic reticulum), encountered by a disease mutant will
bias the folding equilibrium towards the folded state (Fig 2). This principle was first
tested in Fabry patients when Frustaci et al, began a study in which a patient with a
cardiac variant of the late-onset form of the disease received infusions of galactose (1g
galactose / 1kg body mass) every other day for two years. The patient experienced
significant improvements in cardiac health and quality of life [58]. This initial success
showed proof-of-concept, but was far from an ideal treatment option, as it required 4hour infusions of large amounts of galactose every other day. However, this success led
to pre-clinical trials with compounds possessing more desirable clinical properties. One
of these compounds, 1-deoxygalactonojirimycin (DGJ), had previously been shown to
enhance enzyme levels in Fabry lymphoblasts [59]. DGJ, also known as Migalastat,
Galafold, and Amigal, is an iminosugar analog of galactose that acts as a competitive
inhibitor of -GAL [60]. At near-neutral pH, like that of the ER, DGJ binds -GAL with
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a 190,000 fold increase in affinity compared to galactose [10]. This increased affinity is
pH dependent allowing for dissociation of the complex upon entry into the acidic
environment of the lysosome [10]. The high affinity of DGJ towards -GAL coupled
with the pH sensitive of this affinity as well as the pre-clinical results led to it being
entered into clinical trials. After completion of multiple phase III clinical trials of PCT
for Fabry disease, 1-deoxygalactonojirimycin (DGJ) was approved in the US in 2018 and
was approved for the European Union in May 2016.

The studies outlined in this document aim to further the development of new more
efficacious forms of both enzyme replacement therapy and pharmacological chaperone
therapy. Outlined are strategies for the development of more specific pharmacological
chaperones, a more renally efficacious enzyme replacement molecule, and a potentially
novel mechanism for pharmacological chaperone therapy.
.
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45˚

Figure 1. The structure of human -GAL
Human -GAL exists as a homodimer (shown in the top portion of the panel). One
monomer (shown in the bottom of the panel) consists of a β-sandwich domain (shown
in orange, and a catalytic TIM barrel domain. The active site of the monomer is shown
bound to a ligand.
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Figure 2. Overview of α-GAL trafficking
1. Translation initiates in the cytosol and translocation begins as the
N-terminal signal sequence is exposed to translocation machinery.
2.The protein begins to fold as it emerge from the translocation
pore and can either reach its native state or misfold.3.The protein is
trafficked out of the ER towards the lysosome if it has adopted its
native fold or degraded if it has not.
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CHAPTER 2: Interconversion of the Specificities of Human Lysosomal Enzymes
Associated with Fabry and Schindler Disease

Abstract
The human lysosomal enzymes -galactosidase (-GAL, EC 3.2.1.22) and α-Nacetylgalactosaminidase (-NAGAL, EC 3.2.1.49) share 46% amino acid sequence
identity and have similar folds. The active sites of the two enzymes share 11 of 13 amino
acids, differing only where they interact with the 2-position of the substrates. Using a
rational protein engineering approach, we interconverted the enzymatic specificity of GAL and -NAGAL. The engineered -GAL (which we call -GALSA) retains the
antigenicity of -GAL but has acquired the enzymatic specificity of -NAGAL.
Conversely, the engineered -NAGAL (which we call -NAGALEL) retains the
antigenicity of -NAGAL but has acquired the enzymatic specificity of the -GAL
enzyme. Comparison of the crystal structures of the designed enzyme -GALSA to the
wild-type enzymes shows that active sites of -GALSA and -NAGAL superimpose
well, indicating success of the rational design. The designed enzymes might be useful as
non-immunogenic alternatives in enzyme replacement therapy for treatment of lysosomal
storage disorders such as Fabry disease.

Introduction
Lysosomal enzymes are responsible for the catabolism of metabolic products in
the cell. Deficiencies in lysosomal enzymes lead to lysosomal storage diseases,
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characterized by an accumulation of undegraded substrates in the lysosome. In humans,
there are at least 40 different lysosomal storage diseases (including, for example, TaySachs, Sandhoff, Gaucher, and Fabry diseases), each of which is caused by a lack of a
specific enzymatic activity. Fabry disease is caused by a defect in the GLA gene, leading
to loss of activity in the enzyme -galactosidase (-GAL,3 EC 3.2.1.22, also known as
-GAL A)[4]. The -GAL enzyme cleaves substrates containing terminal -galactosides,
including glycoproteins, glycolipids, and polysaccharides. Defects in the GLA gene in
Fabry patients lead to the accumulation of unprocessed neutral substrates (primarily
globotriaosylceramide (Gb3)), which then leads to the progressive deterioration of
multiple organ systems and premature death. Fabry disease is an X-linked inherited
disorder with an estimated prevalence of 1 in 40,000 male births but may be highly
underdiagnosed[1, 4].
The human gene most closely related to the GLA gene is the NAGA gene,
encoding the enzyme -N-acetylgalactosaminidase (-NAGAL, EC 3.2.1.49, also known
as NAGA and -GAL B)[4]. The two genes are derived from a common ancestor[61],
encoding proteins that share 46% amino acid sequence identity (Fig. 3A); they belong to
glycoside hydrolase family 27 and clan D[62]. The -NAGAL enzyme recognizes and
cleaves substrates containing terminal -N-acetylgalactosaminide (-GalNAc) sugars,
and (less efficiently) substrates containing terminal -galactosides. Defects in the NAGA
gene lead to the lysosomal storage disease Schindler disease, characterized by the
accumulation of glycolipids and glycopeptides, resulting in a wide range of symptoms,
including neurological, skin, and cardiac anomalies[4].
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The only approved therapy for the treatment of Fabry disease is enzyme
replacement therapy, where patients are injected with recombinant enzyme purified from
mammalian cell expression systems[8, 13]. One problem with this treatment is that up to
88% of patients develop IgG antibodies against the injected recombinant enzyme[13, 14].
In patients who make no functional -GAL enzyme, the recombinant -GAL used in
enzyme replacement therapy can be treated as a foreign antigen. Because the GLA gene is
located on the X-chromosome, hemizygous males who inherit a non-functional copy of
the gene have no second copy to establish immunotolerance.
Previously, we determined the three-dimensional crystallographic structures of
the human -GAL and -NAGAL enzymes[40, 63]. As expected for two structures that
share 46% sequence identity, the overall folds of the two enzymes are similar (Fig 3B and
3C). Each enzyme is a dimer where each monomer contains an N-terminal ( / )8 barrel
with the active site and a C-terminal antiparallel  domain. The monomers of the two
enzymes superimpose with an r.m.s.d. of 0.90 Å for  378 carbons. The active sites of
the two structures are highly similar, as 11 of the 13 active site residues are conserved.
The only differences in the active sites of the two structures correspond to where the
substrates are different: in -GAL, the residues near the 2-OH on the substrate include
larger glutamate and leucine, whereas in -NAGAL, the larger 2-N-acetyl on the
substrate interacts with the smaller serine and alanine residues on the enzyme (Fig 3B and
3C). As we and others have noted, in glycoside hydrolase family 27, the two residues
primarily responsible for recognition of the 2-position of the ligand are both located on
the same loop in the structure, the 5– 5 loop in the ( / )8 barrel domain[40, 63-67].
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The similarities between the active sites of the enzymes in the family and the
proximity of the two residues responsible for the recognition of the 2-position of the
ligand led us and others to hypothesize that interconversion of the enzyme specificities
would be possible[40, 63, 66-68]. We replaced two residues in the active site of -GAL
(E203S and L206A), leading to a new protein (-GALSA) with the enzymatic specificity
of an -NAGAL enzyme. Additionally, we replaced two residues in the active site of NAGAL (S188E and A191L), leading to a new protein (-NAGALEL) with the
enzymatic specificity of an -GAL enzyme. In this report, we show that the designed
enzymes maintain the antigenicity of the original protein, but have the specificity of the
other enzyme. X-ray crystallographic studies of the -GALSA protein provide a
structural basis for ligand specificity in the family of proteins.

Results
Biochemical Characterization of -GALSA and -NAGALEL
We expressed the four enzymes (-GAL, -GALSA, -NAGAL, and -NAGALEL) in
stably transfected Tn5 insect cells and purified protein from the supernatant. SDS-PAGE
analysis shows that the purified variant proteins migrate at the same size as their wildtype equivalents, 50 kDa for -GAL and -GALSA and 52 kDa for -NAGAL and NAGALEL (Fig 3D). To test the antigenicity of the wild-type and variant proteins, we
performed Western blots on all four proteins using antibodies against human -GAL and
human -NAGAL. -GAL and -GALSA cross-react only with the anti--GAL
antibody, whereas -NAGAL and -NAGALEL cross-react only with the anti-18

NAGAL antibody (Fig 3E), indicating that the variant proteins retain their original
antigenicity.

Enzymatic activity -GALSA and -NAGALEL
We tested the four enzymes against two synthetic substrates, pNP--Gal and pNP-GalNAc. In the wild-type enzymes, the larger active site of -NAGAL allows it to bind
and cleave both substrates, although the pNP--Gal less efficiently. The smaller active
site of -GAL allows for efficient catalysis of pNP--Gal, but no detectable activity on
pNP--GalNAc due to steric clashes between the N-acetyl group on the 2-position of the
sugar and the larger Glu-203 and Leu-206 side chains of -GAL. Table 1 summarizes the
enzyme kinetic data.
The variant enzymes -GAL and -NAGAL show the opposite substrate
specificity compared with their starting wild-type enzymes. The -NAGALEL enzyme
shows the catalytic properties of wild-type -GAL: it has no activity against the pNP-GalNAc substrate, but shows high activity against pNP--Gal. The -GALSA enzyme
has the catalytic properties of wild-type -NAGAL: it has activity against pNP-GalNAc and reduced activity against pNP--Gal.
Because the enzymes in this family have overlapping substrate specificity, we
used the ratio of the specificity constant kcat/KM for the two substrates as a measure of the
ability of the enzymes to discriminate between the two related substrates. The substrate
specificity ratios (kcat/KM)pNP--galNAc /(kcat/ KM)pNP--gal for -GAL and -NAGALEL are
zero, because those enzymes show no activity toward the pNP--GalNAc substrate. The
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substrate specificity ratios for -NAGAL and -GALSA are similar: 57.310.3 for NAGAL and 42.99.0 for -GALSA, showing they have comparable ability to
distinguish between the two substrates.
Comparison of the enzymatic parameters of -GAL and of -NAGALEL (the
enzyme engineered to have -galactosidase activity) shows that the Km values of the two
enzymes are similar (6.9 and 7.6 mM, respectively, for the pNP--Gal substrate). The
engineered enzyme has a turnover number kcat that is ~one-third that of the native -GAL
enzyme (13.7 s-1 versus 37.8 s-1, respectively).
Comparison of the enzymatic parameters of -NAGAL and of -GALSA reveals
that the Km value of the engineered enzyme against the pNP--GalNAc substrate is 30fold larger than that of the wild-type enzyme (21.0 and 0.68 mM, respectively) and 2-fold
larger against the pNP--Gal substrate (49.1 and 27.5 mM, respectively). The turnover
numbers kcat of -NAGAL and -GALSA are similar against the pNP--GalNAc
substrate (15.1 and 21.5 s-1 , respectively) and differ 9-fold against the pNP--Gal
substrate (10.7 versus 1.2 s-1 ). Overall the kinetic parameters show that, although the
engineered enzymes are not as efficient as their wild-type counterparts, they have the
same ability to discriminate among different substrates as their wild-type equivalents. In
particular, the -GALSA engineered enzyme is somewhat less effective at catalyzing the
turnover of substrate compared with its wild-type equivalent, -NAGAL.
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Crystal structure of -GALSA
To examine the structural basis for the reduced catalytic efficiency of the -GAL three
different ligands, N-acetylgalactosamine (GalNAc), galactose, and glycerol (Table 2 and
Fig 4A–C). Superposition of -GALSA and -NAGAL by their (/)8 barrel domains
results in an r.m.s.d. of 0.58 Å for 290 C atoms in the domain. Remarkably, the
superposition of the entire (/)8 domains shows that the GalNAc ligands and the active
site residues superimpose nearly exactly (Fig 4D). Although 54% of the residues differ
between -NAGAL and -GALSA, the ligand superimpose with an r.m.s.d. of 0.38 Å
for the 15 atoms in the ligand.
Superposition of the (/)8 barrel domains of -GALSA and -GAL shows that
the active site residues and ligands superimpose closely, except for Glu-203 and Leu-206
in -GAL, which are replaced with Ser and Ala in -GALSA (Fig 4E). The structure of
-GALSA with galactose bound shows a shift in the location of the catalytic nucleophile
Asp-170 relative to its location in other structures in the family. The Asp-170 nucleophile
shifts into the empty space produced by the reduction in size of the side chain in the
E203S substitution. This shift affects the hydrogen bonding of Asp-170 to Tyr-134 and
Tyr-207, and likely contributes to the reduced catalytic efficiency of the -GALSA
variant protein.
The crystallographic experiments used the cryoprotectant glycerol, which
appeared in the active site of -GALSA. We determined two structures of glycerolsoaked -GALSA in space groups C2221 and P212121. Because each crystal has two
monomers of the protein in the asymmetric unit, we have four crystallographically
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independent active site complexes with glycerol. One of the four glycerol-soaked
monomers shows significant changes in the active site: the glycerol binds in a different
orientation, the Arg-227 side-chain rotamer changes, and the 6–6 loop containing the
catalytic acid/base Asp-231 shifts as well (Fig 4F). This large rearrangement in the active
site is unique to -GALSA among the glycosidase family 27 structures and may also
contribute to the reduced catalytic efficiency of -GALSA.

Discussion
The active site of human -GAL is unable to accommodate 2-N-acetylated
ligands due to steric clashes between the protein and the N-acetyl group on the ligand.
Here, we have engineered -GALSA, the first -GAL enzyme capable of binding GalNAc ligands. In the reciprocal experiment, the engineered -NAGALEL enzyme has
lost all of its activity against -GalNAc ligands and has enhanced activity against galactosides.

Enzyme replacement therapy
Enzyme replacement therapy can successfully treat Fabry disease. However, up to
88% of male patients develop an immune response to the injected recombinant enzyme,
including both IgG- and IgE-based reactions[12-14]. The antigenicity of the
glycoproteins used in enzyme replacement therapy for Fabry disease patients might limit
the effectiveness of the treatment by reducing the amount of enzyme effectively delivered
to the lysosomes. We envision the -NAGALEL molecule would have little
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immunogenicity in Fabry disease patients (who make typical amounts -NAGAL
glycoprotein and are thus immunologically tolerant toward -NAGAL). Consistent with
this, heterozygous female Fabry disease patients (with one wild-type copy of the GLA
gene) do not make the comparable immune responses as their hemizygous male
counterparts against injected enzyme during enzyme replacement therapy[69, 70].
Although patients with the severe form of Fabry disease have little or no -GAL
enzyme activity, patients with the variant forms of Fabry disease can have from 5 to 35%
of wild-type enzyme activity[5, 6]. This suggests that the threshold level of -GAL
enzymatic activity necessary to prevent Fabry disease symptoms is 100% wild-type
activity. Although the enzymatic activity of the engineered proteins is lower than their
wild-type equivalents, in enzyme replacement therapy, the reduced immunogenicity of
the designed proteins might compensate for their reduced activity.
Sakuraba and colleagues have also tested this hypothesis by reporting a protein
similar in design to -NAGALEL, but expressed in Chinese hamster ovary cells, leading
to a different glycosylation pattern[68]. When injected in a mouse model of Fabry
disease, the mammalian-expressed protein led to a reduction in the amount of Gb3 in the
tissues of the mouse. This further suggests that the designed enzyme might act as a useful
tool for the treatment of Fabry disease.

Properties of the engineered enzymes
Western blotting with anti--GAL and anti--NAGAL antibodies shows that the
former reacts only with -GAL and -GALSA, whereas the latter reacts only with NAGAL and -NAGALEL. The sequence divergence between -GAL and -NAGAL is
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sufficient to show no immunological cross-reactivity. Thus, engineering the active sites
of -GAL and -NAGAL to have novel substrate specificities leads to new enzyme
activities without altering antigenicity. This approach may be useful as a general strategy
for protein-based therapeutics where reducing immunogenicity is an issue, such as
Gaucher disease, where 15% of patients on enzyme replacement therapy develop IgG
antibodies to the recombinant enzyme[71].
The diverse sequences in glycoside hydrolase family 27 (which includes human
-GAL and -NAGAL) show high conservation of the active site residues, indicating
strong evolutionary pressure on the active site. One modular component of ligand binding
in the family is the recognition of the 2-position of the sugar ring. In this family, a single
loop on the protein, the 5–5 loop in the N-terminal domain, interacts with the
substituent on the 2-position of the sugar. The similarity across the members of the
family allowed us to interconvert the ligand recognition through substitution of two
residues in the loop. The modularity of the loop is also seen in the structures of other
members of the family, including the rice and Hypocrea jecorina -GAL structures,
where one turn of helix in the 5–5 loop is replaced with a shorter loop and a longer 5
strand[65, 72]. In those structures, Cys and Trp residues fill the space of the Glu-203 and
Leu-206 residue of -GAL or the Ser-188 and Ala-191 residues in -NAGAL.
The newly engineered enzymes -GALSA and -NAGALEL are not as
catalytically efficient as their wild-type equivalents. The structures of -GALSA suggest
that there is considerably more flexibility in the active site of the -GALSA enzyme
when compared with -NAGAL, the enzyme with an identical active site constellation.
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The glycerol-soaked structures of -GALSA provide a structural explanation for the
reduced catalytic efficiency of the engineered enzyme. When the larger Glu-203 and Leu206 residues of -GAL are replaced with smaller Ser and Ala residues in -GALSA, the
active site has more open space in it. This allows the Arg-227 side chain to move toward
the space vacated by the shortening of the Glu-203 side chain, and the 6–6 loop
containing Asp-231 moves toward the space vacated by the shortening of the Leu-206
side chain. The crystal structures indicate that the active site of -GALSA is more
dynamic than the active sites of the wild-type enzymes -GAL and -NAGAL, which
might explain the reduced catalytic efficiency of the designed -GALSA enzyme.
Another indication of the higher mobility of the active site of -GALSA appears in the
glycerol-soaked -GALSA structure, which has higher atomic B-factors in the rearranged
6–6 loop.
In this report, we describe the first instance of bidirectional interconversion of the
enzymatic activities of two human lysosomal enzymes. Rational design of enzymatic
function is a challenging task and generally requires large changes in the active site: for
example, the classic case of conversion of trypsin activity into that of chymotrypsin
required 11 substitutions in 4 sites on the protein[73]. In general, changing substrate
specificity is easier than changing the reaction mechanism of an enzyme[74]. The family
of lysosomal glycosidases might prove to be a fruitful target for further enzyme
engineering, because many glycosidases use a similar mechanism with an arrangement of
two carboxylates located on opposite sides of the glycosidic linkage to be cleaved.
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In conclusion, we have shown the viability of a rational design approach to engineering
new functionality into human lysosomal enzymes. This approach allows for encoding
new enzymatic functions into existing protein scaffolds. By reusing existing proteins in
new ways, our approach avoids the immunogenicity problems that are frequently seen in
enzyme replacement therapies. This approach might also be used for a wide range of
protein-based therapeutics when immunogenicity problems exist.

Experimental Procedures
Molecular biology
Human -GAL and human -NAGAL were expressed in stably transfected Trichoplusia
ni (Tn5) insect cells as described previously[41, 63]. The -GALSA variant was
generated from the wild-type -GAL construct using PCR-based site-directed
mutagenesis (forward primer, 5 -G TAC TCC TGT TCG TGG CCT GCT TAT ATG
TGG-3 (substitutions in bold), and reverse primer, 5 -CAC AAT GCT TCT GCC AGT
CCT ATT CAG GGC-3 ), ligated, transformed into bacteria, and confirmed by
sequencing. The -NAGALEL variant was derived from the wild-type -NAGAL
construct by PCR (forward primer, 5 -CGG CCT CCC CCC AAG GGT GAA CTA-3 ,
and reverse primer, 5 -CC TTC ATA GAG TGG CCA CTC GCA GGA GAA-3 ),
ligated, transformed into bacteria, and sequenced.

Cell transfection
Adherent Tn5 cells in SFX-Insect medium (HyClone) were transfected with plasmid
DNA, and selection for stably transfected cells using 100 µg/ml blasticidin (added after
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48 h and every 48 h for 10 days) was carried out. Stable adherent cells were re-suspended
in SFX medium for larger scale suspension cultures.

Protein expression and purification
One-liter cultures of stable cells secreting -GALSA and -NAGALEL proteins were
grown to 3 X 106 cells/ml. The supernatant was clarified and concentrated by tangential
flow filtration (Millipore Prep/ Scale) and exchanged into Ni2+ binding buffer (50 mM
Na3PO4 , pH 7.0, 250 mM NaCl, 20 mM imidazole, and 0.01% NaN3). The retentate was
loaded onto a Ni2+-Sepharose 6 Fast Flow column (Amersham Biosciences) and eluted
with a gradient of 0 – 60% elution buffer (50 mM Na3PO4, pH 7.0, 250 mM NaCl, 250
mM imidazole, and 0.01% NaN3). Eluate fractions were pooled, desalted, and
concentrated before loading onto a Source 15Q anion-exchange column[63]. Fractions
eluted by a linear salt gradient were screened by activity assays and by Western blots.
Fractions containing pure protein were pooled and concentrated to 1.0 mg/ml for storage.

Kinetic assays
Hydrolysis of the synthetic substrates para-nitrophenyl--galactose (pNP--Gal) and
para-nitrophenyl--N-acetylgalactosamine (pNP--GalNAc) (Toronto Research
Chemicals) at 37°C were monitored by absorbance at 400 nm using an extinction
-1

-1

coefficient of 18.1 mM cm . 0.25–1.2 µg of enzyme in 10 µL of 100 mM
citrate/phosphate buffer (pH 4.5) was added to 12 substrate concentrations (pNP--Gal
from 0.1 to 50 mM, and pNP--GalNAc from 0.01 to 10 mM). Each minute for 10 min,
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the sample absorbance was measured after adding 200 mM Na3BO3 buffer, pH 9.8. Error
bars were determined from triplicate measurements by two experimenters for each data
point. KM, Vmax, kcat, and error bars were determined from a weighted fit of MichaelisMenten hyperbola in KaleidaGraph. Substrate solubility limits prevented saturation in
some experiments. Substrate specificity ratios for each enzyme were defined as
(kcat/KM)pNP--GalNAc /(kcat/KM)pNP--Gal, indicating the preference of an enzyme for
galactosaminide substrates.

Crystallizaton and x-ray data collection
Crystals of -GALSA were grown as described for the D170A -GAL variant[41].
Crystals were obtained from a 1:1 mixture of reservoir solution (12% polyethylene glycol
8,000, 0.1 M sodium cacodylate, pH 6.5, and 22 mM Mg(CH3COO)2) and 7.0 mg/ml
protein in 10 mM Na3PO4, pH 6.5. Crystals were transferred stepwise into reservoir
solution containing 200 mM ligand (GalNAc or galactose) and then into cryoprotectant
solution (15% polyethylene glycol 8,000, 0.1 M sodium cacodylate, pH 6.5, 22 mM
Mg(CH3COO)2, 20% glycerol, and 200 mM ligand). Crystals were flash-cooled in liquid
nitrogen, and x-ray data were collected at 100 K at beamline X6A at the Brookhaven
National Laboratory or at the microfocus beamline NECAT 24-ID-C at Argonne National
Laboratory. X-ray images were processed using HKL2000 [75] and phased by molecular
replacement in AMoRe [76] or by Fourier synthesis using human -GAL coordinates
(PDB: 3HG3)[41]. We selected the overall resolution limits based upon I/1 criteria.
Atomic models were built using the program O [77], with refinement in REFMAC5[76].
Ramachandran plots were computed using PROCHECK [78]. Coordinates were
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superimposed using LSQMAN [79]. Figures were made in MolScript [80] and
POVScript [81]. Coordinates and structure factors are deposited in the Protein Data Bank
under accession codes 3LX9, 3LXA, 3LXB, and 3LXC.
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FIGURE 3. α-GAL and α-NAGAL structural and biochemical analyses
(A) Sequence alignment of the α-GAL and α-NAGAL proteins. Active site residues are red, and
identities have yellow backgrounds. The two active site residues that differ are boxed. (B) and (C),
ribbon diagrams of α-GAL (green) and α-NAGAL (cyan) with attached carbohydrates. Insets show
the active sites of α-GAL and α-NAGAL with their catalytic products -galactose and α-GalNAc,
respectively (gray). 11 of the 13 active site residues are conserved between the enzymes, although
the overall sequence identity is 46%. The two residues that differ (Glu-203 and Leu-206 in α-GAL;
Ser-188 and Ala-191 in α-NAGAL) select for the substituent on the 2-position of the ligand. (D), the
four purified proteins are shown on a Coomassie-stained SDS gel. -GAL and -GALSA (with three
N-linked glycosylation sites each) run smaller on the SDS gel than α-NAGAL and α-NAGALEL
(with five N-linked glycosylation sites each). (E) Western blots of the four proteins, detected with
polyclonal anti-α-GAL (top) and polyclonal anti-α-NAGAL antibodies (bottom). The variant
proteins retain the antigenicity of the original proteins.
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FIGURE 4. α-GALSA crystal structures.
(A–C) σA-weighted 2Fo-Fc total omit electron density maps of α-GALSA calculated in SFCHECK
[36]. (A) GalNAc-soaked crystal contoured at 2.0σ. (B) galactose-soaked crystal contoured at 1.8σ.
(C) glycerol-soaked crystal soaked at 1.0σ. Maps have a cover radius drawn around ligands and/or
waters in the active site. Active site residues are labeled in A. (D) a superposition of crystal
structures of the active sites of α-GALSA and α-NAGAL, each with α-GalNAc bound in the active
site. When the structures are superimposed by their (β/α)8 barrels, the ligands superimpose nearly
exactly. (E) a superposition of crystal structures of the active sites of α-GALSA and α-GAL, each
with -galactose bound in the active site. (F) a superposition of the four monomers of glycerol-soaked
α-GALSA, with glycerol bound in the active site. In one of the four structures (green), the glycerol
binds in a vertical orientation, and shows differences in Arg-227 and the loop containing Asp-231
(arrows).
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CHAPTER 3: The Rational Design of a Potential Second Generation ERT
Therapeutic with Increased Renal Efficacy

Introduction
Fabry disease is an X-linked disorder resulting from mutations in GLA, the gene
encoding -galactosidase (-GAL)[2]. Deficient lysosomal -GAL activity leads to the
accumulation of substrates containing terminal -galactosides, the most prominent being
globotriaosylceramide (Gb3). This accumulation leads to functional impairment of
numerous organ systems including the cardiac and renal systems. Fabry disease is
characterized by chronic neuropathic pain, skin lesions, lenticular and corneal opacities,
angiokeratoma, hypohidrosis, abdominal pain or bloating, as well as cardiac, renal, and
cerebrovascular complications. The average lifespan of a person with the classical form
of Fabry disease is 58 years, and the majority of these individuals receive a kidney
transplant during their life [32]. The incidence rate of classical Fabry disease in males is
estimated to be between ~1:40,000-1:60,000, but based on the screening of newborns it
may be as high as 1:4,600 [1, 4, 82].
One current treatment for Fabry disease is enzyme replacement therapy (ERT).
This treatment involves the intravenous injection of mammalian expressed -GAL,
which is taken into cells through extracellular receptors such as the mannose-6-phosphate
receptor. ERT has been shown to be efficacious for the clearance of Gb3 deposits from
the majority of afflicted tissues [8, 13, 49, 83]. However, the efficacy of ERT towards the
stabilization of renal function appears to be limited. It has been demonstrated that ERT
allows for the clearance of Gb3 deposits from some renal cells, including mesangial cells
and renal endothelial cells, but the effectiveness of the treatment on podocyte depositions
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has recently come into question. In a recent study evaluating long-term ERT on young
patients, podocyte foot process effacement was observed in the majority of patients
despite early administration of ERT [16]. One interpretation of these results is that
despite being treated with ERT, these patients still progress towards more severe kidney
complications.
The podocyte is a highly differentiated epithelial cell type that plays a vital role in
the function of the kidney. Podocytes make up the most distal layer of the glomerular
filtration barrier, which is responsible for filtering blood. The permeability of a molecule
across the glomerular filtration barrier is dependent on its molecular radius and overall
charge [84, 85]. Large molecules and negatively charged molecules are less able to
permeate the barrier. -GAL due to its highly negative charge and dimeric structure is
likely not able to readily permeate the glomerular filtration barrier.
The human -GAL homodimer possesses an overallnegative charge due to a high
number of negatively charged side-chains. Additionally, each monomer contains three
modified N-linked glycans with varying amounts of sialylation and phosphorylation. The
dimer measures approximately 75Å x 75Å x 50Å. The interface between monomers
spans approximately 75Å and buries 2200 Å2 of surface area. Along this interface, amino
acid F273 accounts for 12% of the total surface area (130Å2) (Fig 5). Sequence
alignments of human -GAL with other glycoside family 27 members reveal that this
residue is conserved among dimeric members (Fig 6). The side-chain of F273 packs
against multiple hydrophobic side-chains in the -sandwich domain of the opposite
monomer. In monomeric -galactosidases, such as rice, this position is occupied by a
glycine. The sequence alignment also reveals that there are conserved differences
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between monomers and dimers at the position corresponding to 277 in the human form.
In human and mice -GAL this position is occupied by a tryptophan, and in monomers
this position contains amino acids with smaller side chains. Both of these residues are on
the 7- 7 loop of the ( / )8 domain.
Due to differential conservation of the positions F273 and W277 and the
structural importance of these two positions in the dimer interface, we hypothesized that
substituting these residues would result in a change of oligomeric state. By substituting
these residues with glycines, we have engineered a monomeric enzyme. In this report, we
show through the use of size-exclusion chromatography and in vitro membrane
permeability studies, that the engineered enzyme retains a large fraction of the wild-type
enzyme activity in vitro while existing in a monomeric state.

Results
-GALF273G+W277G retains significant enzymatic activity
To assess the enzymatic properties of -GALF273G+W277G, we used the synthetic
substrate para-nitrophenyl--galactopyranoside (pNP-Gal) to determine KM and kcat
values (Fig 7A). We then used these values to calculate the kinetic efficiency constant,
also known as the specificity constant, of -GALF273G+W277G for comparison to previously
reported values (Fig 7B). The calculated the kinetic efficiency constant of GALF273G+W277G was determined to be 0.375 mM-1 s-1. This value, when compared to the
previously reported value of 5.49 mM-1 s-1 for the wild-type enzyme, reveals an
approximate 15-fold decrease in efficiency.
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The observed enzymatic deficit of -GALF273G+W277G when compared to the wildtype enzyme, is predominantly driven by an increased KM. The calculated KM of GALF273G+W277G of 64.14mM is approximately 10-fold higher than the wild-type enzyme,
6.88mM, whereas the kcat of -GALF273G+W277G, 24.05 s-1 was only slightly lower than
that previously reported for the wild-type enzyme towards the same substrate, 37.8 s-1. It
must be noted that due to the solubility limit of the substrate used for this assay, Vmax and
kcat values cannot be reported with a high degree of certainty.
Overall, these findings indicate that the active site of the engineered enzyme is
less readily saturated, but substrate, once bound, is turned over at a rate comparable to the
wild-type enzyme. It reasons that these findings are the result of increased flexibility of
active site components due to the removal of steric restraints imposed by the packing of
the dimer.

-GALF273G+W277G shows increased membrane permeability
In order to assess the ability of -GAL to permeate a membrane we used the
synthetic membranes in Amicon spin columns. Unfortunately, in vivo experiments would
require an amount of enzyme exceeding our production capabilities, so we opted to
perform in vitro experiments using a synthetic membrane. We applied the wild-type and
mutant -GAL to Amicon spin columns of varying molecular weight cut-offs (3kDa,
30kDa, 50kDa, 100kDa), then spun the columns. The enzyme activity and volume of
both the retentate and filtrate fractions were measured and used to determine the enzyme
units per fraction. The enzymatic units of each fraction were then compared to the total
enzymatic units calculated per sample prior to centrifugation in order to determine
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percent total enzymatic units of each fraction (Figure 8A). The % total enzymatic units of
the filtrate and retentate fractions of the wild-type enzyme remained consistent across the
3 kDa, 30 kDa, and 50 kDa MWCO fractions. With wild-type protein and the 100 kDa
membrane, 36% of the activity appeared in the filtrate, while a significantly smaller
amount, 17.6%, appeared in the filtrate of the 50 kDa. The inverse result was seen in the
retentate samples, with the 50 kDa sample retaining 75.5%, and 63.0% being retained in
the 100 kDa sample. The samples from -GALF273G+W277G show increasing activity in the
filtrate and decreasing activity in the retentate across the 3 kDa, 30 kDa, 50 kDa, and 100
kDa membranes.
We then compared the ratio of % enzyme units in the filtrate to that of the
retentate fraction for each sample (Fig 8B). As expected, the ratio of the two enzymes
was similar for the 3kDa samples. Major differences between the two enzymes in the
filtrate/retentate ratio were observed as the molecular weight cut-off of the membranes
were increased. -GALF273G+W277G showed significant permeation when applied to 30kDa
membrane, this value increased when applied to 50kDa, at which point the amount of
permeation appears to have reached a plateau as the 100kDa samples show a similar
ratio. The wild-type enzyme did not show any change in permeation until the 100kDa
membrane. The ratio of this sample was roughly equivalent to those of -GALF273G+W277G
applied to 50kDa and 100kDa membranes.

-GALF273G+W277G displays altered mobility on size-exclusion columns
In order to determine the molecular weight of -GALF273G+W277G we used size
exclusion chromatography (Fig 9). Sizing standards were used to generate a molecular
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weight standard curve. The elution volume of -GALF273G+W277G maps to a molecular
weight of 39.6 kDa. The elution volume of the wild-type enzyme was calculated to be
81.9 kDa. The estimated molecular weight of -GALF273G+W277G is in good agreement
with the molecular weight of an individual -GAL monomer (43 kDa, based on the
primary amino-acid and three N-linked pauci-mannose carbohydrates). Most importantly,
the approximate 2–fold difference in molecular weight between the wild-type enzyme
and -GALF273G+W277G matches the expected difference between dimeric and monomeric
forms of -GAL.
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Discussion
Human -GAL exists exclusively as a dimer in nature. The extensive dimer
interface buries 2200Å2 of surface area. We have engineered a monomeric form of GAL by introducing 2 amino-acid substitutions and confirmed the quarternary state by
size-exclusion chromatography. -GALF273G+W277G was also shown to more readily
permeate size-selective synthetic membranes. The engineered enzyme retains a
significant portion of the wild-type enzyme activity.
-GALF273G+W277G shows an approximately 15-fold decrease in enzymatic kinetic
efficiency. The primary source of this decreased efficiency appears to be an increased
KM. This decreased ability to achieve active site saturation is possibly the result of
increased active site flexibility. In particular, the 1-1 loop is a likely culprit for this
effect. In the dimeric form of the enzyme, this loop packs extensively against the domain of the opposing monomer and represents a significant portion of the dimer
interface. This loop feeds directly into the active site cavity and is in close proximity to
active site residue W47. Reinforcing this explanation is the fact that this loop exists only
in the dimeric members of glycoside hydrolase family 27, as shown in figure 1. It should
also be noted that this loop is contains numerous negatively charged side-chains, and its
removal may facilitate greater permeability across the glomerular filtration barrier. The
1-1 loop is a prime target for future research aimed at enhancing the enzymatic
efficiency of -GALF273G+W277G derivatives.
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Although the enzyme was shown to have a reduced molecular radius, the effect
these mutations have on the ability of the enzyme to be trafficked to podocytes remains
unanswered as that question exceeds the scope of this study. The two predominant factors
limiting a protein’s permeability across the glomerular filtration barrier are charge and
molecular radius. We have effectively targeted one of these variables, and future studies
may couple the -GALF273G+W277G scaffold with mutations to modify the charge of the
enzyme to generate a superior renal ERT molecule.
Despite the success of ERT in removing substrate deposits from the majority of
afflicted tissue types, the renal efficacy of the treatment has come into question [15].
Patients receiving ERT to treat Fabry disease have been shown to present progressive
renal impairment (in the form of podocyte foot effacement) despite receiving treatment
[16]. Due to the nature of podocytes and their relative position in the glomerular filtration
barrier, deficient ERT delivery is a possible explanation for the progression of renal
complications. -GALF273G+W277G may present an advantageous scaffold for an improved
treatment for the renal complications of Fabry disease. Despite the lower catalytic
efficiency of the enzyme, it has previously been established that 100 percent wild-type
activity is not required to prevent the onset of disease manifestations. A combination of
the current ERT treatment supplemented with an -GALF273G+W277G enzyme may be a
highly effective cocktail as the treatment would retain the efficacy of the current drugs
with the added benefit of an increase in renal delivery.
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Experimental Procedures
Molecular biology
Human -GAL was expressed in stably transfected Trichoplusia ni (Tn5) insect
cells as described previously. The -GALF273G+W27G mutant was generated using the
Phusion site-directed mutagenesis strategy, kinase-treated, ligated, transformed into
DH5 cells, then confirmed by sequencing. The primers used to generate the mutations
were as follows; Forward: 5’-GAT TGG CAA CGG TGG CCT CAG CGG GAA TCA
GCA AG-3’ Reverse: 5’-ACT AAC ATA TCT GGG TCA TTC CAA CCC CCT GGT
CC-3’.

Cell transfection
Adherent Tn5 cells grown in t-25 flasks with serum free IPl-41 media were
transfected with 1.8µg of plasmid using Cellfectin 2. The cells were selected with
100µg/mL blasticidin for 14 days (fresh selective media was applied every 48 hrs). The
cells were allowed to recover in non-selective media for 48 hours and were then
suspended in order to seed larger cultures.

Protein expression and purification
Stably transfected cell cultures were grown in 1L cultures and were harvested
once a high density was reached(~4 X 106 cells/mL). The supernatant from these cultures
was clarified using centrifugation. The clarified supernatant was buffer exchanged into
nickel binding buffer (50 mM sodium phosphate pH 7.0, 250 mM NaCl, .01% azide)
using a tangential flow cartridge. The buffer exchanged supernatant was applied to a 5mL
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Nickel FF column and eluted using a 0-30% linear gradient of elution buffer (50 mM
sodium phosphate pH 7.0, 250 mM NaCl, 400mM imidazole, .01% azide). The fractions
containing -GAL/-GALF273G+W277G were identified using activity assays and coomassie
blue staining. The fractions containing -GAL/-GALF273G+W277G were pooled,
concentrated, desalted, and applied to an Uno Q1 column. The protein was eluted using a
linear salt gradient and the fractions containing pure -GAL/-GALF273G+W277G were
concentrated and stored in 50mM Bis-tris pH 6.0, 100mM NaCl at a concentration of
~1mg/mL.

Size exclusion chromatography
All sizing exclusion experiments were performed using a Superdex 75 5/150 GL
column. The column was pre-equilibrated with a 50mM Bis-tris pH 6.0, 150mM NaCl,
.01% azide buffer prior to each run. A standard curve was generated using molecular
weight standards from Sigma.

Membrane permeability assay
Amicon filters were pre-washed with a 1% bovine serum albumin in 20mM bistris pH 6.0, and spun for 20 minutes at 13100 g. The filters were then loaded with 400µL
of a solution of -GAL, 1% BSA, 20mM bis-tris pH 6.0. The sample was then spun for
15 minutes at 13100 g. The volume of the retentate and filtrate were measured, and 10µL
of each component were applied to 20µL of 20mM pNP--Gal in 100mM
citrate/phosphate buffer at pH 4.5. The reaction was incubated at 37˚C for 10 minutes.
10µL of the reaction was then applied to 190µL of quenching buffer (200mM sodium
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borate pH 9.8). Absorbance readings of the quenched reactions were taken measuring
absorbance at 400nm.

Enzyme kinetics
Enzymatic characterization of -GALF273G+W277G was performed by measuring the
rate of hydrolysis of the synthetic substrate para-nitrophenyl--galactopyranoside (pNP-Gal). The enzyme was mixed with pNP-α-Gal at concentrations ranging from 25µM50mM and incubated at 37˚C for ten minutes with samples being withdrawn every
minute and quenched in 200mM sodium borate pH 9.8. The samples were applied to a
plate reader measuring absorbance at a wavelength of 400nm. Using an extinction
coefficient of 18.1mM-1 cm-1 the concentration of cleaved para-nitrophenyl was
determined, and error bars were calculated using triplicate measurements for each data
point. The KM, Vmax, and error bars were calculated by a weighted Michaelis-Menten
hyperbola using Kaleida-Graph. Due to substrate solubility limitations substrate
saturation was not achieved for the mutant, and as a result substrate specificities, kcat/KM
were used as a comparison to the wild-type enzyme.
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FIGURE 5. Dimer interface of human α-GAL
One monomer is presented a surface representation while the other
is shown as a cartoon. F273 and W277 are shown in yellow. F273
packs extensively against hydrophobic residues of β-domain of the
opposing monomer. W277 has the indole side-chain solvent
exposed.
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Figure 6. Alignment of Representative dimeric or monomeric α-galactosidase
amino sequences
Amino acid sequences of α-galactosidases from various species were chosen to
represent either monomeric and dimeric enzymes. The sequences of dimeric
enzymes are shown in blue with monomers being shown in green.
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Enzyme
WT α-GAL
F273G+W277G

α-GAL

-1

KM (mM)

kcat (s )

kcat/KM

6.88 ± .07

37.8 ± .2

5.49 ± .06

64.14 ± 1.89

24.05 ± .59

0.375 ± .01

F273 + W277

FIGURE 7. Michaelis-menten kinetics of α-GAL
F273 + W277
(A)Michalis-Menten plot of α-GAL
. pNP-Gal was used
as a substrate and product, pNP, was measured by OD at 400nm.
The results of this assay were used to determine Km and kcat ,
these values are shown in (B) as well as those previously
published for the wild-type enzyme.
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Ratio of % Enzyme activity of Filtrate to Retentate
F273 + W277

MWCO

α-GAL

Wild-type

3

.23

.21

30

.38

.22

50

.55

.23

100

.51

.57

FIGURE 8. Enzyme permeability assay using synthetic sizeselective membranes
F273 + W277
Wild-type and α-GAL
enzymes were applied to Amicon
Ultra .5mL spin cartridges of varying molecular weight cut-offs.
Total enzyme units were determined prior to concentrating and the
fraction enzyme activity was calculated for the retentate and filtrate
post concentration as shown in (A). The ratio of percent total
enzyme units in the filtrate to retentate was calculated for both the
F273 + W277
wild-type and α-GAL
and is summarized in the table (B).

48

FIGURE 9. Size-exclusion chromatography elution profiles of wildF273 + W277
type α-GAL and α-GAL
Overlay of the elution chromatogram of wild-type α-GAL (red) and αF273 + W277
GAL
(blue). Elution peaks of sizing standards are represented
by dashed lines.
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CHAPTER 4: α-Homo Variants of Deoxygalactonojirimycin and 2-acetamido1,2-deoxy-D-galactonojirimycin Show Increased Specificity Towards Enzymes
Associated with Fabry and Schindler Disease
Introduction
Fabry disease is an X-linked disorder resulting from mutations in the GLA, the
gene encoding -galactosidase (-gal) [4, 86]. Deficient levels of -gal activity results in
accumulation of glycosphingolipids, primarily globotriaosylceramide (GL-3), in the cells
of a wide array of tissues, and as these deposits accumulate, normal tissue function
becomes impaired [4, 86, 87]. Currently, the two FDA-approved strategies for treatment
of Fabry disease are enzyme replacement therapy (ERT) and pharmacological chaperone
therapy (PCT).
ERT involves the infusion of recombinant human -gal into patients [8, 83]. First
approved in 2001 for use in Europe then in 2003 in the United States, enzyme
replacement therapy has been shown to clear GL-3 deposits from critical organ tissue [8,
13, 49]. Despite the demonstrated efficacy of ERT, there are a number of issues
associated with this treatment. Most obviously, the need for biweekly intravenous
infusion causes significant disruption in a patient’s lifestyle. The treatment is also
extremely expensive, costing approximately $200,000-$300,000 per year [88].
Additionally, the drugs are also unstable at neutral pH, resulting in a short circulating
serum half-life [15, 83]. Limited cellular uptake has also been reported for a number of
cell types such as cardiomyocytes, glomerular podocytes, and the central nervous system
as a whole [15, 83]. When considering all of these issues the prospect of an alternative
treatment led to the advancement of PCT.
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PCT for Fabry disease involves the stabilization of -gal by a small molecule, 1deoxygalactonojirimycin (DGJ), also known as migalastat, AT1001, GR181413A, and
Galafold, that binds and stabilizes wild-type and mutant forms of the enzyme [43, 59].
PCT as a monotherapy received FDA approval in 2018 for a subset of amenable patients
(348 of the 841 known Fabry genotypes as of 2018) [11]. This limited patient pool is the
result of the mutations possessed by non-amenable patients. The GLA genes carried by
these patients either have frameshifts, large deletions or insertion, truncations, or other
mutations that result in a product that is unable to bind DGJ or is too unstable to clear the
endoplasmic reticulum-associated degradation pathway even after chaperone binding
[89]. PCT has been shown to increase -gal activity in cultured cells from amenable
Fabry patients, and this carried over to clinical trials with patients treated showing
increased -gal activity, and the reduction of GL-3 deposits in multiple cell types,
tissues, and organs. [90-92]. A major advantage of DGJ is that it is administered orally
every other day, and does not require intravenous infusions. In addition to its use in the
FDA-approved monotherapy, combination therapy using DGJ; and an enzymereplacement therapeutic has been suggested [93]. In combination therapy, DGJ would act
to stabilize the ERT drug, resulting in an increased circulating serum half-life. The recent
success of DGJ as disease treatment has led to the search for new targets for
pharmacological chaperones, as well as the design of new more effective iminosugar
derivatives.
DGJ is an iminosugar analog of galactose, the product of the reaction catalyzed by
-GAL (Figure 10). The compound is a potent reversible competitive inhibitor of GAL. It has been shown that an interaction between the heterocyclic nitrogen of DGJ and
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the carboxylate of active site D170 is responsible for the 190,000 fold increase in affinity
compared to -galactose, the natural product -GAL catalyzed reactions [10].
Additionally, it has been shown that this affinity is pH-dependent with a significant
decrease in affinity at acidic pH. These characteristics define DGJ as a successful PCT
therapeutic, as the compound binds with the highest affinity in the endoplasmic reticulum
and serum; and a lower affinity in the acidic environment of the lysosome, where it is
required to cleave substrate.
DGJ has also been suggested as a potential treatment option not only for Fabry
disease, but also for the treatment of Schindler/Kanzaki disease [94]. Schindler/Kanzaki
disease results from deficient lysosomal -N-acetylgalactosaminidase (-NAGAL)
activity [95, 96]. -NAGAL and -GAL are evolutionarily linked, having evolved from
the same ancestral gene [40]. As a result, the two enzymes share the same fold and have
highly similar active sites (11 of 13 active residues are conserved). The two different
active site residues are responsible for substrate recognition of groups attached to the C2
position of the substrate sugar. The active site of -NAGAL is capable of binding a
larger N-acetyl group at this position, whereas in the case of -GAL, steric constraints
prevent these compounds from binding. As a result, -NAGAL has less specificity
towards substrates/ligands than -GAL, as illustrated by the ability of -NAGAL to
catalyze the hydrolysis of both terminal -galactosides and -N-acetylgalactosaminides,
as well as its high affinity for DGJ, with a 1.6 µM Ki [63]. It has been shown that
substituting an N-acetyl group for a 2-hydroxyl group of DGJ was sufficient to obtain NAGAL specificity, as demonstrated by 2-acetamido-1,2-deoxy-D-galactonojirimycin
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(DGJNAc) [94]. This modularity allows for a simple approach to convert prospective
Fabry PCT molecules to those specific towards Schindler/Kanzaki disease treatment.
DGJ, at concentrations similar to those used in the clinical trials, has been shown
to inhibit human -galactosidase (GLB1). In fact, DGJ is a potent inhibitor of GLB1 with
a measured Ki of 15µM [94]. The low specificity of DGJ results from the lack of an axial
group on the one position of the iminosugar rings. The active sites of both - and selecting glycosidases have evolved the capability to differentiate between - and linked galactosides. With no 1-hydroxyl group, DGJ suffers from lack of specificity. It is
also possible that some binding affinity is sacrificed by using the 1-deoxy forms of the
iminosugars. For example, crystal structures of both -GAL and -NAGAL with natural
products bound (-galactose and -N-acetylgalactosamine respectively); show hydrogen
bonding between the 1-hydroxyl groups of the ligands and the carboxyl of active site
side-chains D231 in -GAL or D217 in -NAGAL that are not possible within the deoxy
iminosugar analogs.
In this study, we investigated the effect axially linked groups on the C1 position
of galactose or N-acetylgalactosamine analogs have on binding characteristics to human
-GAL or -NAGAL. Using galactonojirimycin (GJ), we investigated the importance of
hydrogen bonding between the 1-hydroxyl of a galactose analog and the carboxylate of
-GAL active site residue D231 in terms of binding affinity. Additionally, we
investigated the effect of  linked groups to C-1 on either Gal-derived or GalNAcderived iminosugars on relative affinity, binding mode, and specificity. Using structural
and enzyme inhibition assays, we determined that additions to the C-1 position of
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iminoalditols have a slightly negative effect on binding affinity towards either -GAL or
-NAGAL, but allow for greater specificity towards their intended targets.

Results
Inhibitory properties of GJ, -HGJ, and -HGJNAc
In order to assay the various compounds in this study, we measured their binding
capabilities using enzyme inhibition assays. The measured Ki of GJ for -GAL was
approximately 2-fold higher than that of DGJ (Fig 11). The slightly weaker binding of GJ
to -GAL may result from the GJ sample consisting of two pseudoanomers. The
difference in binding affinity is small and corresponds to an approximate G of 0.5
kcal/mol compared to DGJ. This increase in G compared to DGJ indicates that the
hydrogen bond gained between -GJ and D231 contributes little to binding affinity.
More significant changes were observed when comparing the binding of homo-2-acetamido-1,2-dideoxy-galactonojirimycin(-HGJNAc) and -homo-1-deoxygalactonojirimycin (-HGJ) to that of DGJ and DGJNAc. -HGJ binds both -GAL and
-NAGAL weaker than DGJ with Ki values 686nM and 2.4µM respectively (Fig 12A
and 12B). These compounds were generously provided by the Bleriot lab [97]. These
values, summarized in table 3, represent an 18-fold increase in Ki against -GAL and a 2fold increase against -NAGAL compared to DGJ. When comparing the binding of HGJNAc to -NAGAL to that of DGJNAc, we observed a 9-fold increase in Ki (440nM
compared to 50nM) (Fig 12C). Taken as a whole, the presence of -linked groups on
either scaffold decreases the ligand’s affinity to their target enzymes.
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Specificity of -HGJ
Specificity is a crucial criterion for the evaluation of a pharmacological
chaperone. DGJ, despite possessing high affinity towards -GAL, has been shown to be
deficient in this regard[94]. We sought to assay the specificity of -HGJ, and we tested
this by comparing activity levels of either -GAL or GLB1 in the presence or absence of
20 µM -HGJ. What we observed was that GLB1 retained 98% of its activity when
incubate with high concentrations of -HGJ. This represents a notable increase in
specificity over DGJ because under similar conditions, DGJ reduced GLB1 levels to
~70% of those observed in the absence of DGJ.

Atomic basis for iminosugar binding
The structures of -GAL + -GJ and -GAL + -HGJ complexes were solved to
further investigate binding of the ligands to -GAL (Table 4). Analysis of both structures
showed little difference in binding compared to that of DGJ (Fig 13 and Fig 14). The GAL + -GJ structure shows well-defined density for -GJ (Fig 13b). Unsurprisingly,
the structure revealed that -GJ utilizes the same binding mode as DGJ as shown in the
superposition of the -GAL + -GJ with -GAL + DGJ (Fig 13a). One clear difference
between the two structures is an additional interaction present in the -GAL + -GJ
structure. This interaction is between the axial hydroxyl group from position 1 of the
sugar ring and the carboxylate of the active site D231. This hydrogen bond has a
measured length of 2.8 Å and corresponds to a bond of moderate strength. Since DGJ
does not possess a hydroxyl at this position, this observation is unsurprising. An
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additional difference between the binding of -HGJ and -GJ to DGJ is an increased
bond length between the carboxylate of D170 and the heterocyclic nitrogen of the ligand
in the respective structures, 2.7 Å in the DGJ structure and 2.8 Å in the -GJ structure.
Slight rotations of -GJ results in a minor shift of the ligand heterocyclic nitrogen
relative to the DGJ structure. It appears this rotation is necessary to accommodate the 1hydroxyl present in -GJ.
The structure of the complex of -HGJ bound to -GAL shows clear density for
-HGJ (Fig 14b). The structure of -GAL + -HGJ contains an interaction not found in
that of the DGJ structure. This hydrogen bond is between the hydroxyl of the
hydroxymethyl at position 1 of the sugar ring and the carboxylate of the active site D231.
This interaction has a measured distance of 3.5 Å, corresponding to a weak hydrogen
bond. As in the case of -GJ and DGJ structures, the -GAL + -HGJ has a preserved
hydrogen bond between the carboxylate of D231 and the hydroxyl at the 2 position of the
iminosugars with a measured distance of 2.6 Å. Unlike what was observed in the -GAL
+ -GJ structure, the ionic interaction between the carboxylate of D170 and the
heterocyclic nitrogen of the sugar ring of -HGJ is conserved with what is observed in
the -GAL + DGJ and maintains a distance of 2.7Å across the two structures. When
aligning the -GJ and -HGJ structures to the active site of the -GAL + DGJ structure,
we observed a more pronounced displacement of the -HGJ relative to the two ligands
(Fig 15). This greater relative displacement may explain the fact that -HGJ has a lower
affinity towards -GAL than GJ and DGJ.
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Discussion
Since it was first reported that infusions of galactose could be used to ameliorate
disease symptoms in a patient suffering from the cardiac variant of Fabry disease, the
application of pharmacological chaperones towards the treatment of Fabry disease was
launched [58]. With the success of DGJ as a pharmacological chaperone as a treatment
for Fabry disease, the application of this strategy towards other lysosomal storage
disorders has become an expanded focus of research. The search for superior PCT
molecules for Fabry disease treatment options has also led to new avenues of research.
One such avenue is the development of more membrane permeable drugs. Initial attempts
to increase permeability involved the design of DGJ derivatives with increased relative
octanol-water partition coefficients through N-alkylation [43]. These initial studies
resulted in a less efficacious molecule, although the field remains open. Other avenues
include the design of drugs that extend the structure of DGJ to bind additional portions of
the active site. These studies found that when treated with 1-deoxygalactonojirimycin
arylthioureas, Fabry fibroblast cells possessed considerably higher -GAL activity than
those treated with DGJ [98]. Another area of research has sought to produce compounds
with a more pH-sensitive mechanism of action as described by Mena-Barragan et al [99].
In this study, we sought to increase the specificity of the DGJ scaffold towards the active
site of -selecting enzymes.
In order for a competitive inhibitor to be a high-quality for PCT, it needs to meet
a number of criteria: it must possess reasonable affinity towards its target (Ki<10µM),
bind reversibly, permeate the ER lumen, and possess high specificity (adapted from Fan
et al. [100]). In the cases of DGJ and DGJNAc, the first two criteria are met through the

57

interaction between the heterocyclic nitrogen of the compound and the active site
carboxylate of D170. At neutral pH, the carboxylate of D170 in -GAL or D156 in NAGAL is deprotonated and forms an ionic interaction with the protonated heterocyclic
nitrogen of DGJ or DGJNAc. Upon entering the acidic environment of the lysosome, the
carboxylate becomes protonated, and the ionic interaction is lost, resulting in a significant
decrease in affinity. Through this mechanism, the compounds are able to stabilize their
targets in the neutral pH of the endoplasmic reticulum and release upon entering the
acidic pH of the lysosome, where they are able to act upon substrate. Despite the pHdependent affinity of DGJ and DGJNAc, both compounds lack specificity, because they
bind enzymes that cleave both α- and β- glycosidic linkages. Both compounds lack the 1hydroxyl of galactose or N-acetylgalactosamine and as a result do not possess specificity
towards - and - selecting hydrolases.
-HGJNAc and -HGJ retain the pH-dependent affinity due to the heterocyclic
nitrogen of the sugar ring. However, -HGJNAc and -HGJ contain a stable -linked
hydroxymethyl group attached to C-1 of the sugar rings. The presence of this group
provides specificity towards -selecting galactosides, as shown by the ability of -HGJ
to inhibit -GAL while showing little inhibitory effect on human β-GAL. This finding
suggests that the addition of an -linked group to C-1 of either a -Gal or -GalNAcderived iminosugar is sufficient to gain specificity towards -GAL or -NAGAL.
However, the α-linked group produces a small penalty on binding affinity. The structural
analysis of -GAL in complex with -GJ and -HGJ reveals that these ligands adopt a
position that is slightly rotated relative to the positioning of DGJ (however, the resolution
of the solved structures limits the precision of the coordinates). The rotation of the ligand
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is necessitated by steric constraints between the ligand functional group and the sidechain of D231. The degree of this rotation is dictated by the nature of the functional
group. The structure of -GAL in complex with -HGJ reveals that the hydroxymethyl
group of -HGJ is positioned in close proximity to the carboxylate of D231. In the case
of -GJ a hydrogen bond exists between the carboxylate of D231 and the hydroxyl group
of -GJ. The enthalpy of the bond and the less restrictive steric restraints result in only a
minor decrease in affinity.
In summary, we have shown that the addition of axially positioned groups to the
C-1 position of a galactonojirimycin scaffold results in increased specificity towards selecting galactosidases. Compounds containing these groups utilize the same binding
mode as the 1-deoxy forms of the compounds and have similar affinities towards their
intended targets. These findings taken as a whole add to our understanding of rational
design of molecules intended for PCT. Despite the slightly reduced binding affinity of
molecules with adducts on the 1 position, the gained specificity decreases the degree to
which off-target binding occurs and may decrease the likelihood of unintended effects
during treatment.

Experimental Procedures
Crystallization and x-ray data collection
Crystals of -GAL were grown using the hanging drop method with a 1:1 mixture
of reservoir solution (8% PEG 8000, 0.1M sodium cacodylate pH 6.5, and 20 mM
Mg((CH3COO)3)2 and 5 mg/mL -GAL in 20mM Bis-Tris pH 6.0. Crystals were
transferred into stabilization buffer (10% PEG 8000, .1M sodium cacodylate pH 6.5, and
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20 mM Mg((CH3COO)3)2 and then into a cryoprotectant solution (14% PEG 8000, .1M
sodium cacodylate pH 6.5, 20 mM Mg((CH3COO)3)2, and 20% glycerol) containing
either 10mM -HGJ or 20mM -GJ. The crystals were then flash-frozen in liquid
nitrogen. X-ray data were collected at the X25 beamline at Brookhaven National
Laboratory. X-ray images were processed using iMosflm and phase determination was
carried out using Fourier synthesis using -GAL coordinates (PDB: 3HG3). Modeling
and refinement were performed using Coot and Refmac5. Figures were prepared using
Pymol.

Protein expression and purification
Expression of -GAL and -NAGAL was accomplished as previously described.
In short, Trichoplusia ni (Tn5) cells expressing either -GAL or -NAGAL were grown
to ~3 x 106 cells/mL at which point the supernatant was separated through centrifugation.
The supernatant was then buffer exchanged into nickel binding buffer (50mM phosphate
buffer pH 7.0, 250mM NaCl, and 40mM Imidazole) using a tangential flow cartridge.
The exchanged supernatant was then applied to a Nickel-FT column and eluted using a
linear imidazole gradient. The fractions containing either -GAL or -NAGAL were
pooled, concentrated, and buffer exchanged into ion exchange binding buffer (50mM
Bis-tris pH 6.0) using an Amicon spin column. The fractions were then applied to a
UNO-Q ion exchange column and eluted with a linear gradient of NaCl. The fractions
containing either enzyme were then concentrated to 1mg/mL.
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Enzyme inhibition assays
0.4µM aliquots of -GAL in assay buffer (100mM citrate/phosphate buffer pH
4.5) were mixed with varying concentrations of -GJ, -HGJNAc, or -HGJ, and
incubated at 4˚C for 30 minutes. 10µL of the enzyme/inhibitor solution was then added to
20µL of 15mM para-nitrophenyl--galactose (pNP--Gal) or 5mM para-nitrophenyl-N-acetylgalactosamine (pNP--GalNAc) and the reaction was incubated for 10 minutes
at 37˚C at which point 10µL of the reaction was added to 290µL of 200mM sodium
borate pH 9.8 in 96-well plates. Abs400 readings of the samples were measured and
product concentrations were calculated using an extinction coefficient of 18.1 mM-1 cm-1.
The averages of triplicate data sets were fitted to semilog sigmoid dose response curves
using Kaleidagraph. IC50 values were calculated and Ki was determined using the
following:
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α-GAL

α-NAGAL

Galactose

16 mM

>16 mM

GalNAc

N/A

13 mM

GJ

84 nM

DGJ

39 nM **

Not
determined
1.5 µM *

DGJNAc

N/A *

51 nM *

α-HGJ

686 nM

2.4 µM

α-HGJNAc

N/A

440 nM

TABLE 3. Summary of Ki Values
Summarization of known inhibitor constants of various compounds against α-GAL
*data previously published by Clark et al [56]
**data previously published by Guce et al [14]
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or α-NAGAL.

FIGURE 13. Structure of α-GAL bound to α-GJ. (A) Superposition
of the active sites of α-GAL bound to DGJ (Grey) (pdb code 3S5Y) and
α-GAL bound to α-GJ (Cyan). (B)Active site of α-GAL bound to α-GJ
with density corresponding to α-GJ and active site residues D231 and
D170 shown. Distance measurements are shown between critical
interactions. (C) Active site of α-GAL bound to DGJ with distances
shown for critical interactions
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FIGURE 14. Structure of α-GAL bound to α-HGJ (A) Superposition of
the active sites of α-GAL bound to DGJ (Grey) (PDB code 3S5Y) and αGAL bound to α-HGJ (Yellow). (B) Active site of α-GAL bound to α-GAL
α-HGJ with density corresponding to α-HGJ and active site residues D231
and D170 shown. Distance measurements are shown between critical
interactions. (C) Active site of α-GAL bound to DGJ with distances shown
for critical interactions

67

FIGURE 15. Comparison of iminosugar binding to α-GAL (A)Pair-fit alignment
of α-HGJ and α-GJ structures to the active site of α-GAL + DGJ. Catalytic residues
aspartic acids 170 and 231 are shown in all structures. α-GAL + DGJ is shown in
grey, α-GAL + α-GJ shown in cyan, and α-GAL + α-HGJ (B) 90° rotated view.
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Data
Ligand Soak
X-ray source
Wavelength, Å
Space group
Cell a, b, c in Å
Cell , ,  in 
Resolution, Å (last shell)
No of observation (last shell)
Unique observation (last shell)
Completeness, % (last shell
Multiplicity (last shell)
Rsym (last shell)
<I/1> (last shell)
Refinement
Rwork / Rfree
Ramachandran: Favored
Allowed
Generous
Forbidden
RMS deviations: Bonds, Å
Angles, 

GJ
BNL X25
1.100
P212121
60.1, 107.9, 183.2
90, 90, 90
69.83 – 2.1 (2.4 – 2.1)
658,185 (91104)
70,812 (10039)
99.7 (98.1)
9.3 (9.1)
0.197 (0.882)
6.5 (2.0)

-HGJ
BNL X25
1.100
P212121
59.6, 106.3, 182.4
90, 90, 90
53.71 – 2.3 (2.4 – 2.3)
492,708 (70063)
52,439 (7543)
100 (100)
9.4 (9.3)
0.082 (0.455)
15.2 (4.2)

0.206 (0.246)

0.197 (0.240)

96.16
3.32
0.26
0.26
.013
1.63

95.8
3.82
0
0.38
0.012
1.58

TABLE 4. Structural Data Collection and Refinement Statistics
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Chapter 5: Conclusions and Future Directions

Lysosomal storage diseases are a class of rare metabolic disease resulting from
insufficient levels of enzymatic activity in the lysosome, resulting in the accumulation of
substrate over time that ultimately leads to the development of disease symptoms.
Normally, the degradative function of the lysosome is achieved through the sequential
action of numerous lysosomal hydrolases that act to catabolize large macromolecules into
smaller components that can then be recycled or expelled from the cell. An individual
lysosomal storage results from the loss of one specific enzyme function, and results in the
normal sequential process of lysosomal degradation halting, and the accumulation of the
substrate specific to the missing enzyme. Due to the monogenic nature of lysosomal
storage diseases, theoretical treatment options for these diseases are fairly simple when
compared to diseases with more complex disease mechanisms. In fact enzyme
replacement therapy, the most widely utilized treatment for lysosomal storage diseases,
was suggested alongside the first study identifying the mechanism for a lysosomal
storage diseases; “In our pathogenic speculations and in our therapeutic attempts, it may
be well to keep in mind that any substance which is taken up intracellularly in an
endocytic process is likely to end up within lysosomes. This obviously opens up many
possibilities for interaction, including replacement therapy” [101, 102].
Despite the conceptual simplicity of enzyme replacement therapy, practical
limitations have led to the need for developing alternate treatment strategies as well as
modifications to ERT drugs. There are numerous universal challenges facing ERT for
lysosomal storage diseases. These include poor cellular uptake of the ERT enzyme into
afflicted cell types. This limitation led to the development of glycan-engineered enzymes
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for the treatment of Gaucher’s and Pompe disease, where these enzymes possess an
increased ability to bind extracellular mannose 6-phosphate receptors and are more
efficiently taken into cells. Low serum half-life is also a universal limitation of ERT as
these enzymes have evolved to act in the acidic environment of the lysosome and are less
stable in the near neutral pH of patient sera. Patient immune response is also a challenge
shared across ERT. An inability to cross blood-brain barrier also limits ERT, under
normal drug administration protocols, and is of particular concern for lysosomal storage
disorders that have neurological implications. In addition to the numerous shared
limitations of ERT, there exist specific limitations for each disease.
In Fabry disease, a major limitation of faced by ERT is incomplete clearance of
Gb3 inclusions from podocyte cells. It has been shown that despite receiving ERT
podocyte cells taken from Fabry patients still contain Gb3 inclusions [15]. Additionally,
it has been observed that patients develop podocyte foot effacement during ERT [16].
Podocyte cells form the last layer of the glomerular filtration barrier and is naturally a
difficult target for a circulating enzyme. Based on the observation that permeability
across the glomerular filtration barrier is inversely related to molecular radius, we sought
to design an engineered form of -GAL with a decreased molecular radius. The
identification of two positions differentially conserved between monomeric and dimeric
forms of glycosyl hydrolase family 27 members allowed us to design a mutant form of
human -GAL that exists in a monomeric state. Our engineered -GAL was shown to
have reduced mobility on a size-exclusion chromatography column and increased
permeability across size selective membranes. The engineered enzyme retained a large
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portion of wild-type enzymatic activity. Our variant -GAL showed signs of reduced
stability when compared to the wild-type form.
The results of this study show that human -GAL can be converted to a
monomeric form and presents a novel strategy to increase efficacy of ERT of podocyte
Gb3 inclusion clearance. Although; the current monomeric variant shows decreased
stability and activity, if these shortcomings were to be addressed through further protein
modification it would represent a promising enzyme for pre-clinical trials. Specifically,
this enzyme would be of particular importance for patients suffering from renal
complications (classical forms and the renal variants of the late-onset form). It could also
potentially be used in combination with the current ERT drugs, which have higher
stability and readily clear Gb3 inclusions from the bulk of tissue. This combination of a
more generic enzyme and one specialized for podocyte cells would retain the general
efficacy of the current drugs but would gain efficacy towards treating podocyte cells.
Another major issue associated with ERT for Fabry disease is immunogenicity.
Eighty-eight percent of patients with the classical form of the disease develop IgG- or
IgE- based reactions to the treatment. Working under the hypothesis that this immune
response results from these patients being immune naïve to correctly folded -GAL, we
engineered a mutant form of -NAGAL possessing the active site of -GAL. This
engineered form of -NAGAL presents itself immunologically as -NAGAL, which we
confirmed testing antigenicity against polyclonal sera raised against -GAL and NAGAL. We also showed that this active conversion did indeed result in a change in
enzyme specificity as the engineered enzyme showed an increase in specificity towards
-galactoside substrate and was no longer capable of catalyzing the hydrolysis of
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substrate with terminal N-acetylgalactosamine sugars. Additionally, we solved the
structure of the inverse conversion, and determined that the binding mode was preserved
when transplanting active sites.
Our engineered -NAGAL strategy is not the only strategy being developed
towards addressing the issue of immunogenicity. Pegunigalsidase alfa is a PEGylated
form of -GAL currently in clinical trials. Initial results indicate that this form of -GAL
is less immunogenic and has a higher serum half-life than current ERT drugs [57]. The
increased serum-half life and lower immunogenicity are promising, but the same
principle limiting immune response, in which the addition of PEG polymers limits
epitope presentation, would also likely lower receptor binding. Additionally, this drug
requires in vitro modifications further complicating drug production.
Our engineered -NAGAL has the benefit of being immunologically neutral
while being nearly as active as the wild-type -GAL. It is an ideal design for gene
therapy and has been used in proof-of-concept studies for gene therapy in Fabry models
by UniQure. These initial studies showed proof of concept and will hopefully warrant
progression towards clinical trials. This advancement is tremendously exciting as
lysosomal storage diseases are prime candidates for gene therapy, due their monogenetic
nature, and the use of this design is particularly appealing, because any immune response
generated would be of dire consequence as gene therapy is non-reversible.
For Fabry disease, pharmacological chaperone therapy is the only currently
approved alternate treatment to ERT and has only recently received approval. DGJ is the
drug used in this therapy and possesses characteristics ideal for PCT. High affinity and
pH dependence are critical to the success of DGJ as a PCT drug. One shortcoming that

73

was identified is a lack of specificity towards α- and β-selecting galactosidases/Nacetylgalactosaminidases [94]. We sought to address this through the use of iminosugars
containing α-linked groups attached to the C1 position of the sugar ring. We found that
these compounds selectively bound α-selecting enzymes with affinities slightly lower
than that of DGJ or DGJNAc. Structural analysis revealed that these compounds utilize
the same ionic interaction, which in DGJ provides the high pH-dependent affinity.
Specificity is of high importance for PCT, because off-target binding has a
number of adverse effects. When off-target binding is present, the intended target
competes with other proteins for binding to the chaperone. This competition may result in
higher dosage of chaperone molecule. In addition to affecting dosages, off-target binding
results in the inhibition of unintended proteins, which poses a risk for averse clinical
effects. The compounds we highlighted in our study provide an alternative to DGJ that
utilize the same pH-dependent mechanism but are retsricted to α-selecting enzymes. This
is an important advancement, because DGJ has been shown to bind unintended targets,
such as β-galactosidase, with relatively high affinity [94].
At the current time, the arrival of second-generation Fabry disease treatments are
on the horizon. There are numerous exciting prospects, such as PEGylated ERT
therapeutics, plant-expressed ERT therapeutics, substrate-reduction therapeutics, and
gene-therapy treatments. Although there is likely to be an increase in treatment options
available to Fabry patients, the opportunity for combination therapies has yet to be
exploited and may provide the most efficacious option for Fabry disease. This
combinatorial approach has already been shown to efficacious through the combination
of current generation of ERT drugs and DGJ in Fabry mouse models [93]. This
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combination showed an increased in recombinant -GAL serum half-life, increased
cellular -GAL levels, and greater Gb3 clearance when compared to ERT alone. The
potential for additional combinations would allow for specialized treatments for different
variations of the disease. For example, a combination of standard ERT therapeutic, PCT
therapeutic, and ERT therapeutic specialized towards renal efficacy would be ideal for
patients with more pronounced renal symptoms, but would not be ideal for a patient with
the cardiac variant of the disease.

Summary
In the studies presented we have described strategies to develop second
generation therapeutics for the treatment of Fabry disease. These strategies address
shortcomings of the current treatment options for Fabry disease. These studies targeted
enzyme replacement therapy and pharmacological chaperone therapy.
One of the shortcomings of enzyme replacement therapy addressed was
immunogenicity. To address the issue of immunogenicity we interconverted the active
sites of -GAL and -NAGAL. We demonstrated that these mutated enzymes have
effectively had their specificities swapped. These interconversions have no effect on the
antigenicity of the enzyme. Structural and enzymatic studies show that these converted
active sites behave comparably to their counterpart wild-type enzymes. These enzymes,
-NAGALEL in particular, are attractive designs for future clinical studies. -NAGALEL
possesses the specificity of -GAL but presents to immune system as -NAGAL.
The second shortcoming addressed is poor podocyte substrate clearance. We
engineered a monomeric form of -GAL, -GALF273G+W277G, and demonstrated that this
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enzyme retains a significant portion of wild-type enzymatic activity. More crucially, this
enzyme was confirmed to more readily permeate size selective membranes. Although,
this enzyme showed signs of reduced stability, it shows promise as a scaffold for other
engineered monomeric -GAL proteins. The goal would be to produce an ERT
therapeutic better able to transverse the glomerular filtration barrier and to clear substrate
from podocyte cells.
Lastly, we identified a strategy to design small molecules that have increased
specificity towards -selecting galactosidases and N-acetylgalactosaminidases as
compared to current pharmacological chaperones for Fabry disease. We demonstrated
that these compounds were excluded from β-galactosidases but were still capable of
binding -GAL and/or -NAGAL with high affinity. Structural studies showed that these
compounds bound -GAL with the same binding mode as DGJ, the current FDAapproved Fabry pharmacological chaperone.
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Appendix
PHARMACOLOGICAL CHAPERONES FOR HUMAN Α-NACETYLGALACTOSAMINIDASE
I made contributions to generating the stable cell lines used for protein
expression. I also contributed to the purification of the proteins used in this study and
performed part of the specificity assays used in this study.
This article is the first to explicitly identify potential pharmacological chaperones
for Schindler/Kanzaki disease. It also lays out a template for designing compounds
specific for α-N-acetylgalactosaminidases, and was the first to identify that DGJ has a
chaperoning effect on α-N-acetylgalactosaminidase.
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HUMAN ACID SPHINGOMYELINASE STRUCTURE PROVIDE INSIGHT TO
MOLECULAR BASIS OF NIEMANN-PICK DISEASE

I made contributions to the identifying crystallographic conditions for the
enzyme. This article has had a large impact in the Niemann-Pick field of research as it is
the first structure of human acid sphingomyelinase. It clarified the catalytic mechanism of
the enzyme and identified the importance of zinc ions in the catalytic mechanism. In
addition to clarifying the catalytic mechanism it also allowed for docking simulations,
which modelled the collaborative process of the separate protein domains required for
substrate hydrolysis.
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LIGAND-PROMOTED PROTEIN FOLDING BY BIASED KINETIC
PARTITIONING

I helped design the eukaryotic experiments in this study and performed these
experiments. This study provides an experimentally validated model for the effect ligand
binding has on protein folding. In addition to testing this model in a prokaryotic model,
this model was validated for the application to a eukaryotic system. This is the first model
created for an FDA-approved pharmacological chaperone in a disease model.
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